<DOC>
	<DOCNO>NCT00532844</DOCNO>
	<brief_summary>This Phase 2 , randomize , open-label , 2-treatment , 2-sequence , 2-period crossover , pharmacokinetic ( PK ) study compare plasma concentration BH4 subject endothelial dysfunction follow 14 day treatment 2 regimen : 6R-BH4 vitamin C 6R-BH4 alone .</brief_summary>
	<brief_title>A Phase 2 , Pharmacokinetic Study Effects 6R-BH4 Alone 6R-BH4 With Vitamin C Subjects With Endothelial Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Willing able provide write , sign informed consent nature study explain , prior researchrelated procedure . Age ≥ 18 year ≤ 75 year . Willing able comply study procedure . If currently receive treatment take follow supplement , willing able discontinue take throughout treatment period : Vit C supplement Multivitamins contain vit C Any dietary supplement , nutraceuticals , thecounter product contain vit C Vitamin Econtaining supplement History cardiovascular disease cardiovascular risk factor , eg , stable wellcontrolled Type 2 diabetes , peripheral arterial disease , obesity , smoking , hypercholesterolemia Endothelial dysfunction , document screen abnormal PAT ≤ 1.70 . Sexually active subject must willing use acceptable method contraception participate study . Females childbearing potential must negative pregnancy test Screening willing additional pregnancy test study . Females consider childbearing potential include menopause least 2 year , tubal ligation least 1 year prior screening , total hysterectomy . Hypertension secondary medical condition ( e.g. , renal failure steroid usage ) . Concurrent disease condition would interfere study participation safety , bleed disorder ; history syncope vertigo ; severe gastroesophageal reflux disease ( GERD ) ; heart failure ; symptomatic coronary disease ; arrhythmia ; serious neurologic disorder , include seizure ; organ transplant ; organ failure . Type 2 diabetic uncontrolled , unstable , newly diagnose , change therapy last three month Type 1 diabetic . Any severe comorbid condition would limit life expectancy &lt; 6 month . Serum creatinine &gt; 2.0 mg/dL , hepatic enzyme concentration &gt; 2 time upper limit normal HIV infection , hepatic cirrhosis , preexist liver disease , positive HIV , Hepatitis B C test screening . Concomitant treatment : Drugs know inhibit folate metabolism ( e.g. , methotrexate ) Levodopa A phosphodiesterase ( PDE ) 5 inhibitor ( e.g. , Viagra® , Cialis® , Levitra® , Revatio® ) A PDE 3 inhibitor ( e.g. , cilostazol , milrinone , vesnarinone ) Use investigational product investigational medical device within 30 day prior screen , requirement investigational agent prior completion schedule study assessment . Myocardial infarction , stroke , surgery within last 60 day prior screen . History alcohol and/or drug abuse positive alcohol drug test screening . Previous treatment formulation BH4 . Has know hypersensitivity 6RBH4 excipients . Pregnant breastfeed screening , plan become pregnant ( self partner ) time study . Any condition , view PI , place subject high risk poor treatment compliance complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>6R-BH4</keyword>
	<keyword>BH4</keyword>
	<keyword>BH4 deficiency</keyword>
	<keyword>sapropterin dihydrochloride</keyword>
	<keyword>endothelial dysfunction</keyword>
	<keyword>NO</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Nitric Oxide</keyword>
	<keyword>Vitamin C</keyword>
</DOC>